Cluster randomized, controlled, triple-blind trial assessing the efficacy of intranasally administered virus-neutralizing bovine colostrum supplement in preventing SARS-CoV-2 infection in household contacts of SARS-CoV-2 positive individuals

niversity of Tartu0 个研究点目标入组 342 人开始时间: 2021年6月14日最近更新: 2022年2月21日

试验速览

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35101094/ (added 02/02/2022)

•Index case:
•1.Confirmed case of COVID-19 infection with at least one SARS-CoV-2 PCR negative person household contact
•2. Aged =16 years
•Household contacts:
•1. SARS-CoV-2 PCR negative household contact of the index case
•2. Aged =16 years

•Current exclusion criteria as of 27/08/2021:
•1. Aged <16 years
•2. Pregnancy
•3. Use of active cancer treatment
•4. Use of biological treatment
•5. Previously confirmed COVID-19
•6. Any organ transplantation
•7. Single person household
•8. Requires hospitalisation prior to study start
•9. Required to take regular medications administered by inhalation, or via the naso- and oropharyngeal route
•10. Asthma
•11. Known allergies to BioBlock components
•Previous exclusion criteria:
•1. Aged <16 years
•2. Pregnancy
•3. Use of active cancer treatment
•4. Use of biological treatment
•5. Previously vaccinated against COVID-19
•6. Previously confirmed COVID-19
•7. Any organ transplantation
•8. Single person household
•9. Requires hospitalisation prior to study start
•10. Required to take regular medications administered by inhalation, or via the naso- and oropharyngeal route
•11. Asthma
•12. Known allergies to BioBlock components

发起方

niversity of Tartu